## Andreas O Zuckermann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6249995/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes. Journal of Heart and Lung Transplantation, 2022, 41, 334-344.	0.3	21
2	Perioperative Risk Factors for Intensive Care Unit Readmissions and Mortality After Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 2339-2343.	0.6	6
3	A Prospective Observational Study on Multiplate®-, ROTEM®- and Thrombin Generation Examinations Before and Early After Implantation of a Left Ventricular Assist Device (LVAD). Frontiers in Medicine, 2022, 9, 760816.	1.2	4
4	ISHLT position paper on thoracic organ transplantation in controlled donation after circulatory determination of death (cDCD). Journal of Heart and Lung Transplantation, 2022, 41, 671-677.	0.3	14
5	Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis. Life, 2022, 12, 361.	1.1	3
6	Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies. European Heart Journal, 2022, 43, 2237-2246.	1.0	23
7	Extracorporeal Photopheresis With Low-Dose Immunosuppression in High-Risk Heart Transplant Patients—A Pilot Study. Transplant International, 2022, 35, 10320.	0.8	6
8	EGR1 Is Implicated in Right Ventricular Cardiac Remodeling Associated with Pulmonary Hypertension. Biology, 2022, 11, 677.	1.3	6
9	Single Donor Infusion of S-Nitroso-Human-Serum-Albumin Attenuates Cardiac Isograft Fibrosis and Preserves Myocardial Micro-RNA-126-3p in a Murine Heterotopic Heart Transplant Model. Transplant International, 2022, 35, 10057.	0.8	1
10	Medical decisions in organ donors and heart transplant candidates with history of COVIDâ€19 infection: An international practice survey. Clinical Transplantation, 2022, 36, .	0.8	3
11	Cardiac Transplantation and Organ Preservation. , 2022, , 167-181.		0
12	ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. Journal of Heart and Lung Transplantation, 2022, 41, 1135-1194.	0.3	17
13	Severe gastroparesis after orthotopic heart transplantation. European Journal of Cardio-thoracic Surgery, 2021, 59, 717-719.	0.6	3
14	The adapted Heart Donor Score. Transplant International, 2021, 34, 546-560.	0.8	3
15	Mass Spectrometry-Based Redox and Protein Profiling of Failing Human Hearts. International Journal of Molecular Sciences, 2021, 22, 1787.	1.8	9
16	Impact of Less Invasive Left Ventricular Assist Device Implantation on Heart Transplant Outcomes. Seminars in Thoracic and Cardiovascular Surgery, 2021, , .	0.4	4
17	Safety and image quality of cardiovascular magnetic resonance imaging in patients with retained epicardial pacing wires after heart transplantation. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 24.	1.6	4
18	Myocardial Angiotensin Metabolism in End-Stage HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1731-1743.	1.2	18

Andreas O Zuckermann

#	Article	IF	CITATIONS
19	Study design and rationale of the pAtients pResenTing with cOngenital heaRt dIseAse Register (ARTORIAâ€R). ESC Heart Failure, 2021, 8, 5542-5550.	1.4	4
20	The Evolution of the ISHLT Transplant Registry. Preparing for the Future. Journal of Heart and Lung Transplantation, 2021, 40, 1670-1681.	0.3	1
21	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric lung transplantation report — 2021; Focus on recipient characteristics. Journal of Heart and Lung Transplantation, 2021, 40, 1023-1034.	0.3	24
22	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report — 2021; Focus on recipient characteristics. Journal of Heart and Lung Transplantation, 2021, 40, 1035-1049.	0.3	132
23	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report — 2021; Focus on recipient characteristics. Journal of Heart and Lung Transplantation, 2021, 40, 1060-1072.	0.3	233
24	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric heart transplantation report — 2021; focus on recipient characteristics. Journal of Heart and Lung Transplantation, 2021, 40, 1050-1059.	0.3	32
25	Donation after circulatory death today: an updated overview of the European landscape. Transplant International, 2020, 33, 76-88.	0.8	168
26	Transplanted stents: a case report. BMC Cardiovascular Disorders, 2020, 20, 312.	0.7	0
27	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult lung transplantation report — 2020; focus on deceased donor characteristics. Journal of Heart and Lung Transplantation, 2020, 39, 1016-1027.	0.3	60
28	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult heart transplantation report—2020; focus on deceased donor characteristics. Journal of Heart and Lung Transplantation, 2020, 39, 1003-1015.	0.3	150
29	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-third pediatric lung transplantation report — 2020; focus on deceased donor characteristics. Journal of Heart and Lung Transplantation, 2020, 39, 1038-1049.	0.3	12
30	Acute oxygenator occlusion in two cases of polycythemia vera: Bailout strategies. Journal of Cardiac Surgery, 2020, 35, 2835-2837.	0.3	2
31	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 23rd pediatric heart transplantation report—2020; focus on deceased donor characteristics. Journal of Heart and Lung Transplantation, 2020, 39, 1028-1037.	0.3	73
32	Molecularâ€level HLA mismatch is associated with rejection and worsened graft survival in heart transplant recipients – a retrospective study. Transplant International, 2020, 33, 1078-1088.	0.8	18
33	HLAâ€EMMA, a tool for molecularâ€level HLA matching after heart transplantation. Transplant International, 2020, 33, 1821-1822.	0.8	О
34	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report — 2019; focus theme: Donor and recipient size match. Journal of Heart and Lung Transplantation, 2019, 38, 1056-1066.	0.3	597
35	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-second pediatric lung and heart-lung transplantation report—2019; Focus theme: Donor and recipient size match. Journal of Heart and Lung Transplantation, 2019, 38, 1015-1027.	0.3	97
36	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-second pediatric heart transplantation report – 2019; Focus theme: Donor and recipient size match. Journal of Heart and Lung Transplantation, 2019, 38, 1028-1041.	0.3	159

#	Article	IF	CITATIONS
37	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: Donor and recipient size match. Journal of Heart and Lung Transplantation, 2019, 38, 1042-1055.	0.3	711
38	Assessment of sympathetic reinnervation after cardiac transplantation using hybrid cardiac PET/MRI: A pilot study. Journal of Magnetic Resonance Imaging, 2019, 50, 1326-1335.	1.9	9
39	An integrated molecular diagnostic report for heart transplant biopsies using an ensemble of diagnostic algorithms. Journal of Heart and Lung Transplantation, 2019, 38, 636-646.	0.3	43
40	The meaning of donor-specific antibodies after heart transplant. Current Opinion in Organ Transplantation, 2019, 24, 252-258.	0.8	16
41	A case report of a 40-year-old woman with endomyocardial fibrosis in a non-tropical area: from initial presentation to high urgent heart transplantation. BMC Cardiovascular Disorders, 2019, 19, 302.	0.7	5
42	Accelerated acute severe antibody-mediated graft failure related to a Ross procedure 17 years earlierâ€. European Journal of Cardio-thoracic Surgery, 2018, 54, 402-403.	0.6	3
43	The management of antibodies in heart transplantation: An ISHLT consensus document. Journal of Heart and Lung Transplantation, 2018, 37, 537-547.	0.3	114
44	mTOR Inhibition and Clinical Transplantation. Transplantation, 2018, 102, S27-S29.	0.5	15
45	High-dose catecholamine donor support and outcomes after heart transplantation. Journal of Heart and Lung Transplantation, 2018, 37, 596-603.	0.3	18
46	Diminished impact of cytomegalovirus infection on graft vasculopathy development in the antiviral prophylaxis era - a retrospective study. Transplant International, 2018, 31, 909-916.	0.8	5
47	A Review of Induction with Rabbit Antithymocyte Globulin in Pediatric Heart Transplant Recipients. Annals of Transplantation, 2018, 23, 322-333.	0.5	7
48	Impact of Donor Core Body Temperature on Graft Survival After Heart Transplantation. Transplantation, 2018, 102, 1891-1900.	0.5	10
49	Cardioprotective cytokine interleukinâ€33 is upâ€regulated by statins in human cardiac tissue. Journal of Cellular and Molecular Medicine, 2018, 22, 6122-6133.	1.6	11
50	Increasing complexity of thoracic transplantation and the rise of multiorgan transplantation around the world: Insights from the International Society for Heart and Lung Transplantation Registry. Journal of Heart and Lung Transplantation, 2018, 37, 1145-1154.	0.3	12
51	The clinical impact of donor-specific antibodies in heart transplantation. Transplantation Reviews, 2018, 32, 207-217.	1.2	52
52	Donor heart selection and outcomes: An analysis of over 2,000 cases. Journal of Heart and Lung Transplantation, 2018, 37, 976-984.	0.3	15
53	Complications of Cardiac Transplantation. Current Cardiology Reports, 2018, 20, 73.	1.3	39
54	Long-term heart transplant outcomes after lowering fixed pulmonary hypertension using left ventricular assist devicesâ€. European Journal of Cardio-thoracic Surgery, 2018, 54, 1116-1121.	0.6	15

ANDREAS O ZUCKERMANN

#	Article	IF	CITATIONS
55	Heart re-transplantation in Eurotransplant. Transplant International, 2018, 31, 1223-1232.	0.8	4
56	Exploring the cardiac response to injury in heart transplant biopsies. JCI Insight, 2018, 3, .	2.3	43
57	BK Virus: A Cause for Concern in Thoracic Transplantation?. Annals of Transplantation, 2018, 23, 310-321.	0.5	10
58	Anti-thrombotic and pro-fibrinolytic effects of levosimendan in human endothelial cells in vitro. Vascular Pharmacology, 2017, 90, 44-50.	1.0	11
59	The recipient's heme oxygenase-1 promoter region polymorphism is associated with cardiac allograft vasculopathy. Transplant International, 2017, 30, 510-518.	0.8	5
60	Impact of Right Ventricular Performance in Patients Undergoing Extracorporeal Membrane Oxygenation Following Cardiac Surgery. Journal of the American Heart Association, 2017, 6, .	1.6	13
61	Urokinase plasminogen activator protects cardiac myocytes from oxidative damage and apoptosis via hOGG1 induction. Apoptosis: an International Journal on Programmed Cell Death, 2017, 22, 1048-1055.	2.2	19
62	Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients. Journal of Heart and Lung Transplantation, 2017, 36, 355-365.	0.3	14
63	Cardiac Surgery After Heart Transplantation: Elective Operation or Last Exit Strategy?. Transplantation Direct, 2017, 3, e209.	0.8	19
64	Analysis of region specific gene expression patterns in the heart and systemic responses after experimental myocardial ischemia. Oncotarget, 2017, 8, 60809-60825.	0.8	18
65	Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. Journal of Transplantation, 2016, 2016, 1-11.	0.3	43
66	Acute Kidney Injury and Outcome After Heart Transplantation. Transplantation, 2016, 100, 2439-2446.	0.5	24
67	Impact of Rabbit Antithymocyte Globulin Dose on Long-term Outcomes in Heart Transplant Patients. Transplantation, 2016, 100, 685-693.	0.5	12
68	A Proposal for Early Dosing Regimens in Heart Transplant Patients Receiving Thymoglobulin and Calcineurin Inhibition. Transplantation Direct, 2016, 2, e81.	0.8	11
69	Donor Selection Criteria: Clinical and Pathological Insights. , 2016, , 115-135.		1
70	Prognostic Impact of Persistent Thrombocytopenia During Extracorporeal Membrane Oxygenation: A Retrospective Analysis of Prospectively Collected Data From a Cohort of Patients With Left Ventricular Dysfunction After Cardiac Surgery. Critical Care Medicine, 2016, 44, e1208-e1218.	0.4	33
71	Transplantation in Austria. Transplantation, 2016, 100, 1785-1787.	0.5	0
72	Clinical significance of the single nucleotide polymorphism TLR2 R753Q in heart transplant recipients at risk for cytomegalovirus disease. Journal of Clinical Virology, 2016, 84, 64-69.	1.6	7

#	Article	IF	CITATIONS
73	Outcome of conservative management vs. assist device implantation in patients with advanced refractory heart failure. European Journal of Clinical Investigation, 2016, 46, 34-41.	1.7	6
74	Influence of antithymocyte globulin treatment of brain-dead organ donor on inflammatory response in cardiac grafts: an experimental study in mice. Transplant International, 2016, 29, 1329-1336.	0.8	2
75	Lymphocyte-depleting induction and steroid minimization after kidney transplantation: A review. Nefrologia, 2016, 36, 469-480.	0.2	11
76	Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II. European Heart Journal, 2016, 37, 2591-2601.	1.0	108
77	Rabbit antithymocyte globulin and donor-specific antibodies in kidney transplantation — A review. Transplantation Reviews, 2016, 30, 85-91.	1.2	32
78	The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. Journal of Heart and Lung Transplantation, 2016, 35, 1-23.	0.3	1,096
79	Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression. Transplant International, 2015, 28, 259-269.	0.8	39
80	Performance of gene-expression profiling test score variability to predict future clinical events in heart transplant recipients. BMC Cardiovascular Disorders, 2015, 15, 120.	0.7	36
81	Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro. Thrombosis and Haemostasis, 2015, 113, 350-362.	1.8	26
82	Hearts Not Dead after Circulatory Death. Frontiers in Surgery, 2015, 2, 46.	0.6	5
83	Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update. Transplant Immunology, 2015, 32, 179-187.	0.6	44
84	The International Society for Heart and Lung Transplantation Registries in the Era of Big Data With Global Reach. Journal of Heart and Lung Transplantation, 2015, 34, 1225-1232.	0.3	11
85	Coronary Pan-Ischemia as a First Sign of a Fulminant Host-Versus-Graft Reaction Eight Years After Orthotopic Heart Transplantation. International Heart Journal, 2015, 56, 679-681.	0.5	2
86	A contemporary review of mechanical circulatory support. Journal of Heart and Lung Transplantation, 2014, 33, 667-674.	0.3	73
87	Lack of donor and recipient age interaction in cardiac transplantation. Journal of Heart and Lung Transplantation, 2014, 33, 629-635.	0.3	16
88	New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin®) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity. Drugs, 2014, 74, 1605-1634.	4.9	57
89	Single-Dose GSTP1 Prevents Infarction-Induced Heart Failure. Journal of Cardiac Failure, 2014, 20, 135-145.	0.7	7
90	Report from a consensus conference on primary graft dysfunction after cardiac transplantation. Journal of Heart and Lung Transplantation, 2014, 33, 327-340.	0.3	523

#	Article	IF	CITATIONS
91	Is it time for a cardiac allocation score? First results from the Eurotransplant pilot study on a survival benefit–based heart allocation. Journal of Heart and Lung Transplantation, 2013, 32, 873-880.	0.3	73
92	Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. Journal of Molecular and Cellular Cardiology, 2013, 60, 16-26.	0.9	145
93	Everolimus immunosuppression in de novo heart transplant recipients: What does the evidence tell us now?. Transplantation Reviews, 2013, 27, 76-84.	1.2	28
94	Induction therapy in heart transplantation: where are we now?. Transplant International, 2013, 26, 684-695.	0.8	33
95	From discrete dilated cardiomyopathy to successful cardiac transplantation in congenital disorders of glycosylation due to dolichol kinase deficiency (DK1-CDG). Heart Failure Reviews, 2013, 18, 187-196.	1.7	36
96	Current strategies and future trends in immunosuppression after heart transplantation. Current Opinion in Organ Transplantation, 2012, 17, 540-545.	0.8	28
97	Two-dimensional speckle tracking echocardiography in heart transplant patients: three-year follow-up of deformation parameters and ejection fraction derived from transthoracic echocardiography. European Heart Journal Cardiovascular Imaging, 2012, 13, 181-186.	0.5	33
98	The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders. Transplantation, 2012, 94, 784-793.	0.5	45
99	Low Serum IGF-1 Is a Risk Factor for Cardiac Allograft Vasculopathy in Cardiac Transplant Recipients. Transplantation, 2012, 93, 309-313.	0.5	3
100	Concordance Among Pathologists in the Second Cardiac Allograft Rejection Gene Expression Observational Study (CARGO II). Transplantation, 2012, 94, 1172-1177.	0.5	126
101	Donor scoring system for heart transplantation and the impact on patient survival. Journal of Heart and Lung Transplantation, 2012, 31, 387-397.	0.3	100
102	Effects of Donor Pre-Treatment With Dopamine on Survival After Heart Transplantation. Journal of the American College of Cardiology, 2011, 58, 1768-1777.	1.2	68
103	Report from a consensus conference on antibody-mediated rejection in heart transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 252-269.	0.3	328
104	Efficacy and Safety of Low-Dose Cyclosporine with Everolimus and Steroids inde novoHeart Transplant Patients: A Multicentre, Randomized Trial. Journal of Transplantation, 2011, 2011, 1-7.	0.3	18
105	Impact of De Novo Everolimus-Based Immunosuppression on Incisional Complications in Heart Transplantation. Transplantation, 2011, 92, 594-600.	0.5	20
106	Is induction therapy still needed in heart transplantation?. Current Opinion in Organ Transplantation, 2011, 16, 536-542.	0.8	13
107	Surgical wound complications after heart transplantation. Transplant International, 2011, 24, 627-636.	0.8	44
108	Association of CD14+ monocyte-derived progenitor cells with cardiac allograft vasculopathy. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 1246-1253.	0.4	11

#	Article	IF	CITATIONS
109	Two-dimensional speckle-tracking strain echocardiography in long-term heart transplant patients: a study comparing deformation parameters and ejection fraction derived from echocardiography and multislice computed tomography. European Journal of Echocardiography, 2011, 12, 490-496.	2.3	44
110	Editorial comment. European Journal of Cardio-thoracic Surgery, 2011, 40, 969-70.	0.6	2
111	Apollon/RNF41 Myocardial Messenger RNA Diagnoses Cardiac Allograft Apoptosis in Rejection. Transplantation, 2010, 89, 245-252.	0.5	1
112	Donor myocardial apollon mRNA is associated with cardiac allograft rejection. Journal of Heart and Lung Transplantation, 2010, 29, 777-785.	0.3	1
113	The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. Journal of Heart and Lung Transplantation, 2010, 29, 914-956.	0.3	1,385
114	Time dependence of estrogen receptor expression in human hearts. Biomedicine and Pharmacotherapy, 2010, 64, 154-159.	2.5	8
115	Donor Serum SMARCAL1 Concentrations Predict Primary Graft Dysfunction in Cardiac Transplantation. Circulation, 2009, 120, S198-205.	1.6	16
116	Age and Outcome After Continuous-Flow Left Ventricular Assist Device Implantation as Bridge to Transplantation. Journal of Heart and Lung Transplantation, 2009, 28, 367-372.	0.3	51
117	Generic Drug Immunosuppression in Thoracic Transplantation: An ISHLT Educational Advisory. Journal of Heart and Lung Transplantation, 2009, 28, 655-660.	0.3	44
118	Clock Genes Display Rhythmic Expression in Human Hearts. Chronobiology International, 2009, 26, 621-636.	0.9	97
119	Heart transplantation in Vienna: 25 years of experience. Wiener Klinische Wochenschrift, 2008, 120, 3-10.	1.0	0
120	Nonâ€melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy. International Journal of Dermatology, 2008, 47, 918-925.	0.5	39
121	Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation. Journal of Heart and Lung Transplantation, 2008, 27, 141-149.	0.3	76
122	Detection of High-grade Stenoses With Multislice Computed Tomography in Heart Transplant Patients. Journal of Heart and Lung Transplantation, 2008, 27, 310-316.	0.3	30
123	Programmed Cell Death in Idiopathic Dilated Cardiomyopathy is Mediated by Suppression of the Apoptosis Inhibitor Apollon. Annals of Thoracic Surgery, 2008, 86, 109-114.	0.7	34
124	Lymphocyte activation and correlation with IMPDH activity under therapy with mycophenolate mofetil. Clinica Chimica Acta, 2008, 394, 67-71.	0.5	13
125	Safety and Efficacy of Statin Therapy in Patients Switched From Cyclosporine A to Sirolimus After Cardiac Transplantation. Transplantation, 2008, 86, 1771-1776.	0.5	21
126	Do Not Transplant if Phlebotomy Would Do. Transplantation, 2008, 85, 1672-1673.	0.5	0

Andreas O Zuckermann

#	Article	IF	CITATIONS
127	Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices. European Journal of Cardio-thoracic Surgery, 2007, 31, 698-702.	0.6	83
128	Matrix metalloproteases and their tissue inhibitor in cardiac transplantationâ~†â~†â~†. European Journal of Cardio-thoracic Surgery, 2007, 32, 48-51.	0.6	11
129	Recommendations for the Use of Everolimus (Certican) in Heart Transplantation: Results From the Second German–Austrian Certican Consensus Conference. Journal of Heart and Lung Transplantation, 2007, 26, 305-311.	0.3	50
130	Ten-year Follow-up of a Prospective, Randomized Trial of BT563/BB10 Versus Anti-thymocyte Globulin as Induction Therapy After Heart Transplantation. Journal of Heart and Lung Transplantation, 2006, 25, 1154-1163.	0.3	29
131	Heart Transplantation Provides Long-Term Survival Benefit in Stable Patients Experiencing Heart Failure Without Reverse Left Ventricular Remodeling. Transplantation, 2006, 82, 1463-1471.	0.5	4
132	Activation of the Purine Salvage Pathway in Mononuclear Cells of Cardiac Recipients Treated with Mycophenolate Mofetil. Transplantation, 2006, 82, 113-118.	0.5	15
133	Differential Role of TGF-beta1/bFGF and ET-1 in Graft Fibrosis in Heart Failure Patients. American Journal of Transplantation, 2005, 5, 2185-2192.	2.6	39
134	In Vivo Measurement of Levofloxacin Penetration into Lung Tissue after Cardiac Surgery. Antimicrobial Agents and Chemotherapy, 2005, 49, 5107-5111.	1.4	36
135	Transplant coronary artery disease: Incidence, progression and interventional revascularization. International Journal of Cardiology, 2005, 104, 269-274.	0.8	36
136	Microsatellite Polymorphism in the Heme Oxygenase-1 Gene Promoter and Cardiac Allograft Vasculopathy. Journal of Heart and Lung Transplantation, 2005, 24, 1600-1605.	0.3	24
137	From Clinical Trials to Clinical Practice: An Overview of Certican® (Everolimus) in Heart Transplantation. Journal of Heart and Lung Transplantation, 2005, 24, S185-S190.	0.3	34
138	Clinical Experience With Certican® (Everolimus) in Maintenance Heart Transplant Patients at the Medical University of Vienna. Journal of Heart and Lung Transplantation, 2005, 24, S206-S209.	0.3	31
139	Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. Journal of Heart and Lung Transplantation, 2004, 23, 1277-1282.	0.3	32
140	Extracorporeal Membrane Oxygenation is Superior to Right Ventricular Assist Device for Acute Right Ventricular Failure After Heart Transplantation. Annals of Thoracic Surgery, 2004, 78, 1644-1649.	0.7	83
141	Thrombophilia Associated with Anti-CD154 Monoclonal Antibody Treatment and its Prophylaxis in Nonhuman Primates. Transplantation, 2004, 78, 1238-1239.	0.5	16
142	Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients1. Transplantation, 2004, 77, 890-897.	0.5	42
143	CD32-Mediated Platelet Aggregation In Vitro by Anti-Thymocyte Globulin: Implication of Therapy-Induced In Vivo Thrombocytopenia. American Journal of Transplantation, 2003, 3, 754-759.	2.6	25
144	Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: One-year results of a 2-center prospective randomized trial. Journal of Thoracic and Cardiovascular Surgery, 2003, 125, 891-900.	0.4	119

#	Article	IF	CITATIONS
145	Computerized heart allograft-recipient monitoring: a multicenter study. Transplant International, 2003, 16, 225-230.	0.8	11
146	Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. Journal of Heart and Lung Transplantation, 2003, 22, 250-257.	0.3	34
147	Sequential big endothelin plasma levels in heart transplant recipients during bridging therapy and after successful heart transplantation. Journal of Heart and Lung Transplantation, 2003, 22, 731-737.	0.3	3
148	Long-term survival (>10 years) of patients >60 years with induction therapy after cardiac transplantation. European Journal of Cardio-thoracic Surgery, 2003, 24, 283-291.	0.6	34
149	Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients. Journal of Heart and Lung Transplantation, 2002, 21, 1074-1079.	0.3	48
150	The University of Vienna experience in heart transplantation. Clinical Transplants, 2002, , 229-42.	0.2	0
151	Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. Journal of Heart and Lung Transplantation, 2001, 20, 511-517.	0.3	101
152	Complete revascularization in coronary artery bypass grafting with and without cardiopulmonary bypass. Annals of Thoracic Surgery, 2001, 71, 165-169.	0.7	137
153	Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients. Clinical Pharmacology and Therapeutics, 2001, 69, 137-144.	2.3	41
154	Pre- and early postoperative risk factors for death after cardiac transplantation: A single center analysis. Transplant International, 2000, 13, 28-34.	0.8	24
155	Response of right ventricular function to prostaglandin E1 infusion predicts outcome for severe chronic heart failure patients awaiting urgent transplantation. Journal of Heart and Lung Transplantation, 2000, 19, 939-945.	0.3	14
156	Pre- and early postoperative risk factors for death after cardiac transplantation: A single center analysis. Transplant International, 2000, 13, 28-34.	0.8	16
157	IMPROVED LONG-TERM RESULTS WITH THYMOGLOBULINE INDUCTION THERAPY AFTER CARDIAC TRANSPLANTATION: A COMPARISON OF TWO DIFFERENT RABBIT-ANTITHYMOCYTE GLOBULINES. Transplantation, 2000, 69, 1890-1898.	0.5	58
158	Transient left ventricular failure following bilateral lung transplantation for pulmonary hypertension. Journal of Heart and Lung Transplantation, 1999, 18, 304-309.	0.3	44
159	Initial experience with two sequential anterolateral thoracotomies for bilateral lung transplantation. Annals of Thoracic Surgery, 1999, 67, 1440-1443.	0.7	19
160	SIMULTANEOUS HEART AND KIDNEY TRANSPLANTATION AS TREATMENT FOR END-STAGE HEART AND KIDNEY FAILURE. Transplantation, 1997, 64, 1129-1134.	0.5	28
161	Are T cells from healthy heart really only passengers? Characterization of cardiac tissue T cells. Immunology Letters, 1996, 53, 63-67.	1.1	14
162	EARLY ONSET OF PULMONARY MUCORMYCOSIS WITH PULMONARY VEIN THROMBOSIS IN A HEART TRANSPLANT RECIPIENT. Transplantation, 1996, 62, 1185-1187.	0.5	14

#	Article	IF	CITATIONS
163	ICD therapy in survivors of sudden cardiac death awaiting heart transplantation. Annals of Thoracic Surgery, 1995, 59, 916-920.	0.7	8
164	Phenotypic Patterns of Mononuclear Cells in Dilated Cardiomyopathy. Circulation, 1995, 92, 2876-2885.	1.6	35
165	Treatment of non-healing skin ulcers with autologous activated mononuclear cells. European Journal of Vascular Surgery, 1994, 8, 351-356.	0.9	33
166	TUBERCULOSIS OF TWO CARDIAC ALLOGRAFTS IN ONE PATIENT. Transplantation, 1994, 57, 1277-1278.	0.5	1
167	Monitoring of mononuclear cell subsets isolated from the coronary sinus and the right atrium in patients after heart allograft transplantation. Journal of Thoracic and Cardiovascular Surgery, 1991, 102, 215-223.	0.4	4
168	Indications, Complications, and Outcomes of Cardiac Surgery After Heart Transplantation: Results From the Cash Study. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	4